Target intelligence / Profile preview

DnaJ homolog subfamily C member 7 (DNAJC7)

Target
DNAJC7
Molecular classification
Co-chaperone, Molecular chaperone, Hsp40 family member, J-domain protein (JDP), class C, Tetratricopeptide repeat (TPR) protein
01

Overview

DnaJ homolog subfamily C member 7 (DNAJC7) is a co-chaperone protein in the Hsp40 (DNAJ) family, containing three tetratricopeptide repeat (TPR) domains and a C-terminal J domain. It is primarily expressed in neuronal tissue and plays an essential role in protein homeostasis, especially by regulating the folding, stabilization, and degradation of client proteins in cooperation with molecular chaperones Hsp70 and Hsp90. DNAJC7 acts as a bridge, facilitating transfer of substrate proteins between Hsp70 and Hsp90, and is critically involved in the suppression of pathogenic tau protein aggregation—a hallmark of Alzheimer’s disease and other tauopathies. Mutations in DNAJC7 have been linked to familial forms of amyotrophic lateral sclerosis (ALS) and can exacerbate protein aggregation and neuronal toxicity by disrupting chaperone-mediated quality control. As such, DNAJC7 is considered a potential therapeutic target for the treatment of protein aggregation disorders associated with neurodegenerative diseases

Other names
TPR2TTC2TPR repeat protein 2DJ11DJC7tetratricopeptide repeat domain 2DnaJ heat shock protein family member C7DnaJ (Hsp40) homolog, subfamily C, member 7
02

Mechanism of action

Modulation/enhancement of protein quality control via chaperone interaction; Inhibition or facilitation of protein aggregation (notably tau aggregation); Regulation of cellular stress response through interaction with Hsp70/Hsp90 and HSF1-mediated pathways

03

Biological functions

Protein homeostasis (proteostasis)Folding of client proteinsRegulation of tau protein aggregationCellular stress responseFacilitation of heat shock responseProtein quality controlTransfer of client proteins between Hsp70 and Hsp90 chaperone cycles
04

Disease associations

Neurodegenerative diseaseAmyotrophic lateral sclerosis (ALS)Tauopathies (including Alzheimer's disease, frontotemporal dementia)Protein aggregation disorders
05

Safety considerations

Disturbance of protein homeostasis with inhibition or loss of DNAJC7 may increase susceptibility to neurodegenerationMutations can result in a toxic gain-of-function, especially in ALS
06

Interacting drugs

MG132 (experimental, proteasome inhibitor used to study chaperone/proteostasis pathways)

1 more in the full profile.

07

Biomarkers

DNAJC7 genetic mutations (biomarker of ALS risk)Tau aggregation and seeding activity in neurodegenerative diseaseHSF1 transcriptional activity (downstream; regulated by DNAJC7 function)

Beyond the preview

Go deeper on DnaJ homolog subfamily C member 7 (DNAJC7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DnaJ homolog subfamily C member 7 (DNAJC7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call